readthroughSign in
Jul 23, 2026Financing8 fact check notes

China Pharma Holdings prices $5 million registered direct offering at $2.00 per share

The Nevada holding company will sell 2.5 million shares to an institutional investor, with closing expected July 23, 2026 and FT Global Capital as placement agent.

The related securities purchase agreement, signed July 22, 2026, gives the investor the right to participate in up to an amount equal to 40% of the company's subsequent financings for three months after closing1, and bars the company from entering new share issuance agreements or variable rate transactions until 91 calendar days after closing, subject to certain exceptions.1

The offering's underlying shelf registration carries conflicting dates across the company's own filings. The 8-K states the shares are offered under an effective shelf registration statement on Form S-3, initially filed with the SEC on January 14, 2024 and declared effective February 14, 2024, under File No. 333-276481.1 The press release attached to that same 8-K instead says the shelf was filed on Form F-3 on January 12, 2024 and declared effective February 14, 2024, under the same File No. 333-276481.1 The prospectus supplement filed the same day corroborates the January 12 date, stating the company filed a registration statement on Form S-3, File No. 333-276481, on January 12, 2024, which was amended on February 6, 2024 and declared effective by the SEC on February 14, 2024.2 The filing date and form type therefore differ between the 8-K body text and the other two documents; the February 14, 2024 effective date and the 333-276481 file number match across all three.

Per the prospectus supplement, the offering would leave 43,022,002 shares of common stock outstanding, up from 40,522,002 before the sale.2 The company estimated net proceeds of approximately $4.4 million after placement agent fees and offering expenses.2 CPHI shares closed at $8.10 on NYSE American on July 21, 2026,2 the trading day before the offering was priced at $2.00 per share.

Fact check notes

  • ImpreciseThe filing date and form type differ between the 8-K body text and the other two documents; effective date and file number match across all threeThe filing-date discrepancy (8-K's Jan 14 vs both others' Jan 12) is accurate, and the effective date/file number matching across all three is accurate. However, the form-type claim is overstated: the 8-K and prospectus supplement both say 'Form S-3'; only the press release says 'Form F-3'. So form type does NOT differ between the 8-K and the prospectus supplement—only between the press release and the other two documents. The entry mischaracterizes which document is the outlier for form type.
  • Checker's noteThe entry states the form type 'differs between the 8-K body text and the other two documents,' but the 8-K and the prospectus supplement both cite Form S-3; only the press release cites Form F-3. The characterization of which document is the outlier for form type is inaccurate.
  • Sentence removedChina Pharma Holdings, Inc. (NYSE American: CPHI) announced on July 22, 2026 the pricing of a registered direct offering of 2.5 million shares of common stock at a purchase price of $2 per share.copied source wording
  • Sentence removedThe gross proceeds from the offering will be $5 million before deducting placement agent fees and other offering expenses.copied source wording
  • Sentence removedThe company intends to use the net proceeds for working capital and general corporate purposes.copied source wording
  • Sentence removedThe offering is expected to close on or about July 23, 2026.copied source wording
  • Sentence removedFT Global Capital, Inc. is acting as the exclusive placement agent for the offering.copied source wording
  • Sentence removedUnder the placement agency agreement, the company agreed to pay FT Global a cash fee equal to 7.0% of the aggregate proceeds received from the sale of its securities.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.